www.fdanews.com/articles/196531-izana-begins-trial-of-rheumatoid-arthritis-drug-for-covid-19
![Izana logo](https://www.fdanews.com/ext/resources/test/Drug-Images4/Izana-logo.gif?t=1586212543&width=430)
Izana Begins Trial of Rheumatoid Arthritis Drug for COVID-19
April 7, 2020
Izana Bioscience has initiated a two-center compassionate use study of its drug namilumab for treatment of patients with rapidly worsening COVID-19.
Namilumab is a human monoclonal antibody therapy that targets granulocyte-macrophage colony stimulating factor. It is currently in late-stage clinical development for the treatment of rheumatoid arthritis and ankylosing spondylitis.